LAMPRENE SUMMARY
Lamprene®
Lamprene, clofazimine, is an antileprosy agent available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye.
Lamprene is indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. Lamprene has not been demonstrated to be effective in the treatment of other leprosy-associated inflammatory reactions.
Combination drug therapy has been recommended for initial treatment of multibacillary leprosy to prevent the development of drug resistance.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Lamprene (Clofazimine)
Leprosy
Source: MedicineNet Alopecia Areata Specialty [2017.09.08]
Title: Leprosy
Category: Diseases and Conditions
Created: 6/10/2009 12:00:00 AM
Last Editorial Review: 9/8/2017 12:00:00 AM
Published Studies Related to Lamprene (Clofazimine)
Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. [2007.06]
BACKGROUND & AIMS: Mycobacterium avium subspecies paratuberculosis has been proposed as a cause of Crohn's disease. We report a prospective, parallel, placebo-controlled, double-blind, randomized trial of 2 years of clarithromycin, rifabutin, and clofazimine in active Crohn's disease, with a further year of follow-up... CONCLUSIONS: Using combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for up to 2 years, we did not find evidence of a sustained benefit. This finding does not support a significant role for Mycobacterium avium subspecies paratuberculosis in the pathogenesis of Crohn's disease in the majority of patients. Short-term improvement was seen when this combination was added to corticosteroids, most likely because of nonspecific antibacterial effects.
Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. [2005.10]
OBJECTIVE: To evaluate the efficacy of clofazimine (CFZ) compared with chloroquine diphosphate (CDP) for the treatment of cutaneous involvement in systemic lupus erythematosus (SLE)... CONCLUSION: These findings suggest that CFZ is equally as effective as CDP in controlling cutaneous lesions in SLE patients. However, we cannot exclude the possibility that the CFZ itself could be the cause of systemic lupus flare.
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations
with pretomanid and bedaquiline. [2015]
monotherapy and in combinations with Pa and B... CONCLUSIONS: B-Pa-Z, including two novel agents without resistance in prevalent
Treatment of recurrent aphthous stomatitis with clofazimine. [2009.11]
OBJECTIVE: The aim was to investigate the safety and efficacy of clofazimine for the treatment of recurrent aphthous stomatitis... CONCLUSION: Clofazimine should be considered for the treatment of recurrent aphthous stomatitis.
Use of clofazimine in dermatology. [2009.09]
Clofazimine is the riminophenazine dye that, due to its antibacterial and anti-inflammatory properties, has been used for several diseases. This article reviews all major characteristics and uses relating to clofazimine, from its pharmacology to its indications in several skin diseases, over and above its classical and well established use in the treatment of leprosy.
Clinical Trials Related to Lamprene (Clofazimine)
Effect of Additional Clofazimine on Erythema Nodosum Leprosum (ENL) Reactions in Leprosy [Completed]
Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy [No longer available]
Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World
Health Organization and the National Hansen's Disease Program consider clofazamine to be
standard therapy for treatment of multibacillary leprosy. In recent years, the availability
of the drug has become limited and is currently available only under a research protocol and
is considered "investigational." Use of Clofazamine in patients presenting with lepromatous
leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other
therapies. This drug will be used prospectively for patients who require treatment of
leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.
Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z) [Active, not recruiting]
The trial will evaluate the extended bactericidal activity of 14 consecutive days of oral
administration of TMC207 plus PA-824 plus Pyrazinamide plus Clofazimine, TMC207 plus PA-824
plus Pyrazinamide, TMC207 plus PA-824 plus Clofazimine alone, TMC207 plus Pyrazinamide plus
Clofazimine, Pyrazinamide alone, Clofazimine alone, and standard first line TB treatment as
per South African TB Guidelines (Rifafour e-275) as determined by the rate of change of log
CFU per ml sputum over the time period Day 0-14 in participants with smear positive
pulmonary tuberculosis (TB). A control group will receive standard treatment.
A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease [Completed]
This study will examine the effectiveness of clofazimine in the prophylaxis of Mycobacterium
avium complex infection in HIV infected individuals who are at risk to develop this
untreatable opportunistic disease. In the absence of truly effective antiretroviral therapy,
a potential mode of treatment of patients with HIV infection is to prevent the development
of the life-threatening opportunistic infections. Current studies demonstrate a possible
efficacy of clofazimine in the prophylaxis against Pneumocystis carinii pneumonia (PCP), the
most common AIDS-defining opportunistic infection. Future studies will examine the potential
for prophylaxis against the other opportunistic infections. This proposal hopes to define
the role of prophylactic clofazimine in preventing the currently untreatable Mycobacterium
avium complex infection. AMENDED: To include prophylaxis for Asymptomatic and ARC.
A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. [Completed]
To compare the effectiveness and toxicity of two combination drug treatment programs for the
treatment of disseminated Mycobacterium avium infection in HIV seropositive patients. [Per
03/06/92 amendment: to evaluate the efficacy of azithromycin when given in conjunction with
either ethambutol or clofazimine as maintenance therapy.] Disseminated M. avium infection is
the most common systemic bacterial infection complicating AIDS in the United States. The
prognosis of patients with disseminated M. avium is extremely poor, particularly when it
follows other opportunistic infections or is associated with anemia. Test tube studies and
clinical data indicate that the best treatment program may include clofazimine, ethambutol,
a rifamycin derivative, and ciprofloxacin. Test tube and animal studies indicate that
amikacin is a bactericidal (bacteria destroying) drug that works better when used with
ciprofloxacin. Its role in treatment programs is a key issue because of toxicity and because
it must be administered parenterally (by injection or intravenously).
|
|
|
|
Page last updated: 2017-09-08
|
